Docoh
Loading...

XNCR Xencor

News

From Benzinga Pro
JNJ, Xencor Sign $1.3B Licensing Deal For B-Cell Malignancies-Targeted Bispecific Antibody
4 Oct 21
Biotech, News, Health Care, Contracts, Small Cap, Movers, Trading Ideas, General
Xencor Enters Global Collaboration And License Agreement With Janssen To Advance Plamotamab And XmAb CD28 Bispecific Antibody Combinations For The Treatment Of Patients With B-Cell Malignancies; Xencor To Receive $100M Upfront Payment And $25M Equity Investment And Is Eligible For A Mid-teen To Low-twenties Percent Royalty For Plamotamab And Potential Milestone Payments Up To $1.188B
4 Oct 21
News, Contracts, Small Cap
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced an exclusiveXencor, Inc.
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
27 Aug 21
Biotech, News, Penny Stocks, Small Cap, Top Stories
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26)
Return on Capital Employed Insights for Xencor
20 Aug 21
Earnings
After pulling data from Benzinga Pro it seems like during Q2, Xencor (NASDAQ:XNCR) earned $9.09 million, a 157.98% increase from the preceding quarter. Xencor also posted a total of $67.45 million in sales, a 98.58% increase since Q1.
Stocks That Hit 52-Week Lows On Friday
20 Aug 21
News, Intraday Update, Markets, Movers, Trading Ideas
On Friday morning, 155 companies achieved new lows for the year.
Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China
17 Aug 21
Biotech, News, Health Care, Contracts, Small Cap, General
SVB Leerink Maintains Outperform on Xencor, Lowers Price Target to $53
5 Aug 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Jonathan Chang maintains Xencor (NASDAQ:XNCR) with a Outperform and lowers the price target from $57 to $53.
Xencor Q2 EPS $0.87 Up From $(0.61) YoY, Sales $67.45M Up From $13.09M YoY
4 Aug 21
Earnings, News
Xencor (NASDAQ:XNCR) reported quarterly earnings of $0.87 per share. This is a 242.62 percent increase over losses of $(0.61) per share from the same period last year. The company reported $67.45 million in sales this
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
4 Aug 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3)
Earnings Scheduled For August 4, 2021
4 Aug 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
1 Aug 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories, General
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

Press releases

From Benzinga Pro
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
4 Oct 21
Press Releases
-- Second agreement with Janssen on bispecific antibodies directed toward the CD28 co-stimulatory receptor on T cells -- -- Xencor to receive $100 million upfront payment and $25 million equity investment and is
Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting
1 Oct 21
Press Releases
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced five poster
Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference
20 Sep 21
Press Releases
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company
Xencor Reports Second Quarter 2021 Financial Results
4 Aug 21
Press Releases
-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of
Xencor to Present at Upcoming Investor Conferences
2 Aug 21
Press Releases
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company
Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021
28 Jul 21
Press Releases
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release